The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
Site Search
Showing 31 - 40 of 105 results
News
|
|
2 min read
News
|
|
2 min read
News
|
|
1 min read
News
|
|
3 min read
Check in with your cystic fibrosis care team several months before your trip.
6 min read
Tezacaftor/ivacaftor (Symdeko™) is approved for individuals with two copies of the most common cystic fibrosis mutation, F508del, as well as for individuals who have a single copy of one of 26 specified mutations -- regardless of their other mutation.
News
|
|
4 min read
Celtaxsys Inc. reported promising results today from an early stage clinical trial of a potential anti-inflammatory drug for people with cystic fibrosis.
News
|
|
2 min read
Going on vacation without your child with cystic fibrosis can be hard, but here are some tips to help make it a little easier.
Jaclyn Strube
News
|
|
2 min read
With the holidays fast approaching, it's time to prepare for the change of schedule in your cystic fibrosis routine.
Susie Rider